It has long been recognized that IL-6 promotes tumor growth and survival (36), with elevated levels of circulating IL-6 detected in patients with untreated mCRPC or CRPC (37, 38), and serum levels correlated with shorter survival time (39). This evidence concerns the gene IL6 and neoplasm.